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Introduction. 18F-FDG-PET visualises inflammation. Both atherosclerosis and giant cell arteritis cause vascular inflammation, but
distinguishing the two may be difficult. The goal of this study was to assess interobserver agreement and diagnostic accuracy of
18F-FDG-PET for the detection of large artery involvement in giant cell arteritis (GCA).Methods. 31 18F-FDG-PET/CT scans were
selected from2databases. Four observers assessed vascularwall 18F-FDGuptake, initiallywithout and subsequentlywith predefined
observer criteria (i.e., vascular wall 18F-FDG uptake compared to liver or femoral artery 18F-FDG uptake). External validation was
performed by two additional observers. Sensitivity and specificity of 18F-FDG-PETwere determined by comparing scan results to a
consensus diagnosis. Results. The highest interobserver agreement (kappa: 0.96 in initial study and 0.79 in external validation) was
observed when vascular wall 18F-FDG uptake higher than liver uptake was used as a diagnostic criterion, although agreement was
also good without predefined criteria (kappa: 0.68 and 0.85). Sensitivity and specificity were comparable for these methods. The
criterion of vascular wall 18F-FDG uptake equal to liver 18F-FDG uptake had low specificity. Conclusion. Standardization of image
assessment for vascular wall 18F-FDG uptake promotes observer agreement, enables comparative studies, and does not appear to
result in loss of diagnostic accuracy compared to nonstandardized assessment.
1. Introduction
18F-Fluorodeoxyglucose Positron Emission Tomography
(FDG-PET), usually combined with low-dose CT (FDG-
PET/CT), may be used to detect vascular wall inflammation
[1]. The most common causes of vascular wall inflammation
are, by far, atherosclerosis and vasculitis, particularly giant
cell arteritis (GCA). An infectious etiology (e.g., syphilis)
is far less common [2–4]. Therefore, the primary goal for a
clinician is to differentiate between GCA and atherosclerotic
plaque inflammation when vascular wall 18F-FDG uptake is
present [5]. GCA, a granulomatous vasculitis of unknown
origin, may present clinically as temporal arteritis which
is characterised by temporal headache, jaw claudication
and visual symptoms. Large arteries are frequently involved
[6]. However, temporal arteries are not always affected.
This clinical phenotype, in which the clinical presentation
is less specific, has been referred to as “silent,” “occult” or
large-vessel vasculitis (LVV) [7, 8].
Several criteria for the qualitative (visual) assessment
of FDG-PET for the detection of large artery involvement
in GCA have been introduced, ranging from “increased”
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 914692, 8 pages
http://dx.doi.org/10.1155/2015/914692
2 BioMed Research International
circumferential 18F-FDG uptake (i.e., not further specified)
in a segment of the arterial wall to equal or more intense
vascular wall uptake than liver uptake [9–12].
It has been recommended that only those with specific
expertise and experience should assess vascularwall 18F-FDG
uptake [9]. In clinical practice, and in our own experience,
interobserver agreement among such experts is not always
sufficient. However, this has been tested in only a few studies
(Table 1) As low levels of agreement are problematic, since
they preclude diagnostic accuracy [13], the primary objective
of this study was to establish interobserver agreement for
the visual assessment of vascular wall 18F-FDG uptake using
various scoring methods. As a secondary objective, different
FDG-PET/CT scoringmethods were compared with the final
clinical diagnosis.
2. Methods
2.1. Patient Characteristics. 31 FDG-PET/CT scans were
selected from the databases of the Department of Nuclear
Medicine and PET Research of the VU University Medical
Center (VUMC) and the Department of Nuclear Medicine
and Molecular Imaging of the University Medical Center
Groningen (UMCG). These FDG-PET/CT scans were per-
formed in clinical practice in order to (1) determine the cause
of inflammation of unknown origin (𝑛 = 12) (this was a
subset of patients from a study addressing the value of FDG-
PET in patients with systemic inflammation of unknown
origin) [14], (2) investigate whether large-vessel vasculitis was
present in patients with diagnosed temporal arteritis (𝑛 = 6)
or polymyalgia rheumatic (PMR) (𝑛 = 7), or (3) do a follow-
up procedure in patients with a history of cancer (𝑛 = 6)
who were considered to be in clinical remission, from which
a random selection was made.
The first two groups were selected as a high incidence of
large-vessel vasculitis was expected. A diagnosis of temporal
arteritis (according to the ACR criteria for GCA) [15] or
PMR (in accordance with Healy criteria) was made by
the treating physician. Two patients with a diagnosis of
temporal arteritis and one patient with a diagnosis of PMR
used prednisone prior to the FDG-PET/CT scan. The third
(reference) group was selected because malignancy is the
most common indication for an FDG-PET/CT scan making
these scans easy to obtain. In addition, the incidence of large-
vessel vasculitis was expected to be low. Table 2 shows patient
characteristics of these groups.
A Philips Gemini TOF (VUMC) and a Siemens Biograph
(UMCG) PET/CT scanner (Philips Medical Systems, Eind-
hoven, Netherland and Siemens Medical Systems, Knoxville,
TN) were used. A standardised protocol according to Euro-
pean Association of Nuclear Medicine (EANM) guidelines
was used for the acquisition of scans [16]. In short, after
fasting for at least four hours, whole-body (from head to
knees) or total-body (from head to toes) PET-scans were
acquired 60 (±5) minutes after intravenous injection of
3MBq/kg 18F-FDG. A low-dose CT scan was acquired prior
to the PET-emission scan for attenuation correction and
anatomic localization. Each scan was given a specific study
Table 1: Overview of articles reporting imaging findings in
GCA/large-vessel vasculitis and assessment of observer agree-
ment of visual assessment. (n.r.: not reported, 18F-FDG-PET: 18F-
fluorodeoxyglucose positron emission tomography, MRI: magnetic
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code before analysis assuring that observers were blinded for
original scan report and clinical data. Finally, the observers
were unaware of the number of patients with large-vessel
vasculitis that were included. Blinding for medical center was
impossible because PET/CT scans from two different vendors
were used.
2.2. Image Analysis. Four observers used three distinctmeth-
ods to visually (qualitatively) assess 18F-FDG vascular wall
uptake (vascular uptake). These methods were applied in a
consecutive manner in all scans and were consistently used
by the observers. The level of experience varied among the
observers, that is, 12, 8, 5 (three nuclear medicine physicians),
BioMed Research International 3
Table 2: Patient characteristics, total and ordered by group.




rheumatica (𝑛 = 7)
Control group
(𝑛 = 6)
Age (years)∗ 70 (12) 73 (13) 67 (10) 73 (7) 62 (13)
Sex (female)∙ 65% 58% 100% 57% 50%
ESR (mm/h)∗ 70 (32) 79 (27) 64 (42) 58 (30) Unknown
BMI (kg/m2)∗ 23,4 (7,3) 23,7 (8,6) 23,3 (4,6) 21,6 (9,9) 25 (1,7)
∗Mean (standard deviation), ∙percentage.
and 2 years (one general physician working as a researcher in
the field of PET/CT and large-vessel inflammation).
First, vascular uptake was assessed without using prede-
fined criteria and was therefore based on first impression.
This method was selected as it is often used in clinical
practice, due to the absence of established observer criteria
(qualitative and quantitative), such as comparing vascular
uptake with uptake in other organs (e.g., the liver). Vascular
wall uptake was scored as 1: normal, 2: atherosclerosis, or
3: large-vessel vasculitis (method (I)). The term large-vessel
vasculitis was used as temporal artery involvement cannot be
assessed using PET/CT due to a relatively low resolution of
the scan and potential spill over from adjacent (physiological)
brain 18F-FDG uptake [5].
Subsequently, the intensity of vascular uptakewas system-
atically compared with the intensity of 18F-FDG liver uptake
and scored as 0: absent, 1: less intense, 2: equally intense, or 3:
more intense (method (II)).
The arterial segments that were studied in these first
two methods included carotid, vertebral, subclavian, iliac,
and femoral arteries, the aortic arch, and the ascending,
descending, and abdominal aorta.
In the third method, femoral artery uptake was chosen
as reference since the femoral artery is rarely involved in
GCA and has a high incidence of atherosclerosis [17, 18]. The
intensity of vascular uptake in the other arterial segments was
compared with the intensity of femoral artery uptake and was
scored as 0: less intense, 1: equally intense, or 2: more intense
(method (III)).
The distribution pattern, either focal (in all segments
<2 cm) or diffuse (at least one segment comprisingmore than
2 cm of contiguous vascular wall uptake), and presence of
arterial calcification on low-dose CT were also scored.
After the first reading, a consensusmeeting was held with
the goal to clarify causes of disagreement.
Finally, interobserver agreement was calculated using
definitions of large-vessel vasculitis for each of the applied
methods. These definitions were
(I) first impression (no predefined criteria),
(IIa) diffuse vascular wall uptake, equal to or higher than
liver uptake in more than one vascular segment,
(IIb) diffuse vascular wall uptake, higher than liver uptake
in more than one vascular segment,
(III) diffuse uptake, higher than femoral artery uptake.
2.3. Clinical Diagnosis of Large Artery Involvement in GCA.
To date, there is no clinical reference standard for a diagnosis
of large artery involvement in GCA (either with or without
temporal artery involvement). Furthermore, there is no
consensus on which imaging modality or imaging criteria
should be used.Therefore, in order to compare FDG-PET/CT
results to a clinical diagnosis of large artery involvement in
GCA, we defined the latter as
(1) temporal arteritis according to ACR criteria [15],
accompanied by an FDG-PET/CT scan that was
unanimously classified as large-vessel vasculitis by all
observers for at least one of the methods applied,
(2) inflammation (i.e., elevated ESR) of unknown origin,
not fulfilling ACR criteria for GCA, accompanied by
FDG-PET/CT results that were unanimously classi-
fied as large-vessel vasculitis by all observers for at
least two of the methods applied.
In both groups, a good clinical response to immuno-
suppressive therapy (prednisone), defined as rapid resolution
of signs and symptoms, accompanied by normalisation of
inflammatory parameters, was mandatory for the diagnosis.
Additionally, no other diagnosis was allowed to have been
established during a follow-up period of at least 3 months.
This clinical diagnosis was used to determine sensitivity
and specificity for the 4 FDG-PET/CT scoring methods.
2.4. External Observers. Based on the results of the first
four observers, the definitions of large-vessel vasculitis that
showed high levels of agreement between observers and with
the clinical diagnosis were used for external validation. The
first four observers are employees at a university hospital and
have specific interest and experience in large-vessel vasculitis
and PET/CT reporting. Therefore, two community hospital
nuclear medicine physicians were asked to score the same
scans by these definitions. Again, interobserver agreement
was determined.
2.5. Statistical Analysis. Levels of agreement were quantified
using Fleiss’ kappa (𝜅) for multiple raters and Cohen’s kappa
for two raters. 𝜅-values are reported using the benchmarks
of Landis and Koch (with 0.81–1 being almost perfect agree-
ment; 0.61–0.8 being substantial agreement; 0.41–0.6 being
moderate agreement; 0.21–0.4 being fair agreement; 0.01–0.2
being slight agreement; and ≤0 being poor agreement) [19].
The statistical program 𝑅 was used to calculate Fleiss’ kappa
4 BioMed Research International
Table 3: Average number of vasculitis PET/CT scores (individual observer scores), Fleiss’ kappa, sensitivity, and specificity (95%-CI)
according to the different methods applied.
Method Average number of vasculitides (𝑥1, 𝑥2, 𝑥3, 𝑥4) Fleiss’ kappa Sensitivity
∗ Specificity∗
(I) First impression 9 (6, 9, 10, 11) 0,68 92% (52–98%) 90% (70–97%)
(IIa) Diffuse uptake,
≥liver uptake 16 (14, 16, 17, 18) 0,78 100% (61–100%) 60% (39–78%)
(IIb) Diffuse uptake,
>liver uptake 7 (7, 7, 7, 8) 0,96 100% (61–100%) 98% (82–100%)
(III) Diffuse uptake,
>femoral artery uptake 7 (6, 6, 6, 10) 0,81 80% (41–94%) 96% (79–99%)
∗The average sensitivity and specificity of the results of the 4 observers (𝑥1–𝑥4) were calculated.
[20]. SPSS was used to calculate Cohen’s kappa (SPSS version
20; SPSS inc.).
3. Results
3.1. First Impression Potentially Influences Comparison to
Liver. After all scans were analysed, a remarkably high
disagreement (i.e., 1/3 of all cases) was noticed when vascular
uptake was compared to liver uptake. In a subgroup of
patients vascular uptake was scored as less intense than liver
uptake by some of the observers, whereas it was scored
equally intense by other observers. During the consensus
meeting, the observers concluded that in some cases vascular
wall uptakewas considered to be less intense than liver uptake
based on their first impression that large-vessel vasculitis
was not present. Therefore, a reanalysis of these scans was
performed. Furthermore, the observers agreed that vascular
uptake was only consistent with vasculitis if it showed a
diffuse uptake pattern. The presence of calcification was
ignored as it was present in all patients on low-dose CT scans.
3.2. Interobserver Agreement. Table 3 shows the average
number (and individual scores of all 4 observers) of scans
that were scored as large-vessel vasculitis. A remarkably high
number of large-vessel vasculitis diagnoses were made when
definition (IIa) was used. Figure 1 shows examples of FDG-
PET/CT images in which there was complete agreement on
absence or presence of large-vessel vasculitis according to all
methods (Figures 1(a) and 1(c)) and an image in which there
was disagreement (Figure 1(b)) according to method (II).
All observers agreed in 21 of 30 cases (70%) when
assessing scans according to method (I). The corresponding
Fleiss’ kappa was 0,68 (0,72 without the results of the least
experienced observer).
There was agreement between all observers in 19 of 30
patients (63%) when scoring according to method (IIa), and
kappa was 0,78 (0,81 without results of the least experienced
observer) (Table 3). When method (IIb) was applied, there
was agreement between all observers in 29 of 30 cases (97%),
resulting in a kappa of 0,96 (1 without the results of the least
experienced observer).
Finally, for method (III), all observers agreed in 27 of
30 cases (90%) with a resulting kappa of 0,81 (1 without the
results of the least experienced observer).
3.3. PET/CT Results and Clinical Diagnosis. In 4 patients
(13%), we were unable to obtain sufficient follow-up data to
ascertain a clinical diagnosis. One patient (from the group of
inflammation of unknown originwhowas suspected of large-
vessel vasculitis after PET/CT) died the week after the scan
was performed; autopsy was not performed. Three patients
were lost to follow-up. In the remaining 27 patients, a clinical
diagnosis of large-vessel vasculitis was established in 6 (22%)
according to the previously mentioned criteria. The average
sensitivity and specificity for all definitions are shown in
Table 3. All definitions provide high sensitivity and specificity,
with the exception of a low specificity for definition (IIa).
Of 6 patients with temporal arteritis, 4 had large artery
involvement on FDG-PET/CT according to all observers.
Two of these four patients had a negative temporal artery
biopsy, whereas one biopsy was inconclusive (not arterial
tissue). The two patients with a negative FDG-PET/CT scan,
both, had a positive temporal artery biopsy. One of the
7 patients with PMR had large-vessel vasculitis on FDG-
PET/CT when using definition (IIa), whereas no large-vessel
vasculitis was present using definitions (IIb) and (III).
3.4. External Observers. Table 4 shows the results of the
external observers. Definition (IIa) was not used in the
external validation because of low specificity in the first
analysis. Agreement between the 2 observers was high using
definitions (I) and (IIb) and moderate using definition (III).
Sensitivity of definition (I) was highest, whereas definitions
(IIb) and (III) had the highest specificities.
4. Discussion
Our study suggests a preference for standardized observer
criteria for the assessment of large-vessel vasculitis on 18F-
FDG-PET/CT images. Among dedicated and experienced
observers, assessment of diffuse vascular uptake that exceeds
liver uptake provides the highest observer agreement. Addi-
tionally, sensitivity and specificity appear to be superior,
although the results show considerable overlap in the con-
fidence intervals, at least partly due to the limited number
of patients in this study. Among less experienced observers,
agreement was more or less similar for standardized criteria
(i.e., comparing vascular uptake to liver uptake) versus “first
impression.” Altogether, standardization of imaging criteria
BioMed Research International 5
(a) (b)
(c)
Figure 1: 18F-FDG PET/CT scans showing: (a) Maximum intensity
projection (MIP) image: scored as large-vessel vasculitis by all
observers according to all methods, (b) coronal image: 18F-FDG
uptake in descending aorta (arrow) scored as equal to liver uptake
(arrowhead) by 2 observers and lower than liver uptake by 2 other
observers, none of the observers scored higher than liver or femoral
artery uptake, (c) MIP image of a PMR patient that was scored
negative for large-vessel vasculitis by all observers. (Cerebral and
urinary tract 18-18F-FDG uptake are physiological).
is equal to or superior to using first impression. In addition,
standardization of imaging criteria will undoubtedly facilitate
communication, both in clinical practice and in science,
bearing in mind the increasing use of FDG-PET/CT in
clinical practice and hence the assessment of vascular 18F-
FDG uptake by observers with varying degrees of experience.
High interobserver agreement was suggested in two
previous studies which also compared vascular uptake with
liver uptake [10, 12]. In these observer-blinded studies, only
two experienced observers assessed all scans, potentially
reducing generalizability of their findings. In addition, only
one method was used to assess uptake in these studies. As in
most studies, vascular uptake was considered to reflect large-
vessel vasculitis when uptake was equal to or higher than liver
uptake. Our findings challenge the specificity of this criterion
and suggest overestimation of the prevalence of large-vessel
vasculitis using this definition. However, misclassification of
our control patients cannot be excluded, since our criteria for
the clinical diagnosis of large-vessel vasculitis were relatively
strict. In addition, it has been suggested that immunosuppres-
sive therapymay attenuate vascular uptake and hence require
different interpretation (i.e., loss of sensitivity of definition
(IIb)) [23]. Two of our patients (with a clinical diagnosis
of temporal arteritis) used prednisone. In both, vascular
uptake was not higher than liver uptake (one equal to and
one less intense than liver uptake), and they did not fulfil
our clinical criteria for large-vessel vasculitis. Regrettably,
absence of histological proof, as is virtually always the case,
precludes a definitive diagnosis. Finally, most of the earlier
studies were performed using a stand-alone 18F-FDG-PET
scanner. Modern (i.e., “hybrid”) PET/CT scans may be more
sensitive, due to attenuation correction, thereby potentially
detecting vascular uptake (either resulting fromphysiological
processes, atherosclerosis, or low-grade/subclinical inflam-
mation/vasculitis) in large arteries in “healthy” controls [34].
Our study has some strengths and limitations. One of the
strengths is that observer agreement was studied in a group
of observers with a varying degree of experience, enhancing
the generalizability of the results. Additionally, external
validation by nonacademical nuclear medicine physicians
confirmed the results, which is important as many studies
addressing this topic are performed solely in an academic
setting. In clinical practice, FDG-PET/CT scans will be
assessed by nuclearmedicine physicians or radiologists with a
varying amount of clinical experience. The clinical reference
standard that we constructed is also a strength of this
study. Although we do realise that the definitions we used
to establish a clinical diagnosis of large-vessel vasculitis
are not universally accepted diagnostic criteria, we at least
made a serious attempt to relate imaging tests to a clinical
diagnosis. Our proposed criteria incorporate themost impor-
tant characteristics of GCA (clinical signs and symptoms,
inflammation and rapid response to steroids) and a consensus
among multiple observers regarding imaging characteristics
of vasculitis in large arteries. This approach enabled us to
establish that changing the cut-off value for 18F-FDG uptake
(higher than liver uptake as opposed to equal to or higher)
did not seem to affect sensitivity of the clinical diagnosis
but increased specificity. Another strength is the application
of different criteria in a single study to investigate whether
one definition possesses both high interobserver agreement
and diagnostic accuracy. In the current study, vascular wall
uptake was also compared with femoral artery uptake, as we
have experienced that, in the elderly (i.e., patients over 50
years of age), the femoral artery invariably displays 18F-FDG
uptake. It remains to be elucidated whether this results from
atherosclerotic plaque inflammation, which is known to be
common in the elderly [18], or from physiological activity.
Large-vessel vasculitis infrequently involves femoral arteries
[17]. Although using vascular wall uptake in the femoral
artery as reference has a theoretical drawback of a lower
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Table 4: Average number of vasculitis PET/CT scores (individual observer scores), Cohen’s kappa, sensitivity, and specificity (95%-CI)
according to the different methods applied.
Method Average vasculitis score (𝑥1, 𝑥2) Cohen’s kappa Sensitivity
∗ Specificity∗
(I) First impression 10 (9, 11) 0,85 100% (61–100%) 88% (67–96%)
(IIb) Diffuse uptake,
>liver uptake
6 (5, 7) 0,79 83% (46–95%) 100% (84–100%)
(III) Diffuse uptake,
>femoral artery uptake
7 (7, 7) 0,63 83% (44–97%) 93% (73–98%)
∗The average sensitivity and specificity of the results of the 2 observers (𝑥1–𝑥2) were calculated.
sensitivity (when the femoral artery is involved in the disease
process, as observed in our study), its specificity and degree
of observer agreement render it a good alternative when liver
uptake is unclear (e.g., in patients with liver diseases causing
nondiffuse liver uptake).
A limitation is the absence of a true reference standard for
the diagnosis of large-vessel vasculitis, which would need to
be histopathological evidence.Obviously, our clinical diagno-
sis comprises the test under study which may introduce bias.
However, as a “practical gold standard” to establish large-
vessel vasculitis is currently not present, we believe that this
approach may be a first step towards establishing such a gold
standard. We are inclined to think that the criteria we used
for a patient to be classified as a large-vessel vasculitis patient
were appropriate.
The limited sample size may also be considered a
limitation. Although we included patients with inflamma-
tion of unknown origin and apparently healthy patients
(after follow-up for malignancy) as controls, which further
enhances the external validity of our study, the limited size of
all groups warrants corroboration in a larger group of similar
patients. Finally, it has been suggested that not two but four
characteristics might differentiate vasculitis from atheroscle-
rotic plaque inflammation [5].These include intensity of vas-
cular wall uptake (vasculitis beingmore intense), distribution
pattern (vasculitis being more diffuse and affecting primar-
ily the thoracic arteries, subclavian, and vertebral arteries,
whereas atherosclerotic plaque inflammation is supposed
to be focal, mainly affecting the abdominal aorta and the
iliofemoral arteries), calcification (atherosclerosis patients
havingmore calcification), and quantification of FDGuptake.
Our study mainly addressed the first two characteristics.
Calcification was also assessed in all patients. However, as 28
of 30 patients displayed calcification on low-dose CT (results
not shown) this characteristic was not expected to con-
tribute to differentiation. Moreover, quantitative assessment
in patients with atherosclerotic disease has suggested that
vascular inflammation is lower in vascular segments showing
calcification [35–37], although studies are not unequivocal
[38]. Using a semiquantitative approachmay help to incorpo-
rate calcification in the differentiation between patients with
GCA and atherosclerosis [38]. Standardized uptake values
(SUVs) may be calculated in regions of interest (ROIs) in the
vascular wall (whether SUVmax or SUVmean should be used
remains to be established) and in the liver to determine ratios.
5. Conclusion
In conclusion, predefined standardized criteria (comparing
vascular uptake to liver uptake) have high interobserver
agreement and probably have good diagnostic accuracy for
large-vessel vasculitis. All patients with a clinical diagnosis of
large-vessel vasculitis displayed diffuse vascular wall uptake
higher than liver uptake. We recommend that observers
consider scans with these characteristics to be consistent with
large-vessel vasculitis when using modern PET/CT scanners.
In case of irregular liver uptake, femoral artery uptake may
be used as an alternative reference standard, bearing in mind
that sensitivity might be slightly lower if the femoral artery
is involved in the disease process. Finally, these results may
not apply to patients that used steroids prior to the FDG-
PET/CT scan. Future studies need to address the effect of
steroids on vascular uptake (i.e., establishing time interval
between start of steroids and resolution of characteristics on
FDG-PET/CT) and the potential value of semiquantitative
methods (SUVs).
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